TLR3 and hepatocellular carcinoma: Cytokines, such as FMS-like tyrosine kinase 3 ligand (Flt3L), are able to attract DC, which can subsequently be activated by adjuvants, like toll-like receptor (TLR) agonists.263PolyIC, a synthetic TLR3 agonist, induces activation and maturation of conventional DC type 1264and is currently tested in combination with anti-PD-1 in HCC patients (NCT03732547).